Targeted Therapy
Approved for: NSCLC
Biomarker: NTRK
Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.
FDA-Approved Lung Cancer Treatments
Larotrectinib (Vitrakvi)
I want to give in honor of...
name or relation
Donation Amount
other amount